TLR2 and acute lymphoblastic leukemia: For example, Rolf and colleagues (54) demonstrated that stimulation of acute lymphoblastic leukemia (ALL) cell lines and primary ALL samples with the specific TLR1/2 agonist, PAM3CSK4, versus the TLR2/6 agonist, PAM2CSK4, led to distinct activation kinetics of the NF-κB and PI3K pathways.